11. Because the teratogenicity of ramucirumab is not known, the patient, if sexually active, must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods) for the entire duration of the study including a minimum of 12 weeks after dosing has been completed. Female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to enrolment. Women must not be breastfeeding.